Corey S. Goodman - 02 Feb 2026 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ALXO
Reported as of: 02 Feb 2026
Net transaction value: +$4,999,999
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:15:59 UTC
Prior SEC filing: 21 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Shelly Pinto, by power of attorney

Filing notes and source

Key filing fact

Corey S. Goodman filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 04 Feb 2026.

Key facts

This page summarizes Corey S. Goodman's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Feb 2026, 16:15.

Change

Previous filing in this sequence was filed on 21 Jan 2026.
Current net transaction value: +$4,999,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001278411 Primary reporting owner

GOODMAN COREY S

Relationship: Director, 10%+ Owner
Address: C/O VENBIO PARTNERS, LLC, 1700 OWENS STREET, SUITE 595, SAN FRANCISCO
Signature: /s/ Shelly Pinto, by power of attorney
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALXO transaction

Common Stock

Purchase

Transaction value: $4,999,999
Shares: +3,184,713
Change %: +60%
Price: $1.57
Shares after: 8,453,038
Date: 02 Feb 2026
Ownership: See footnote
Footnotes: F1

ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,969,789
Date: 02 Feb 2026
Ownership: See footnote
Footnotes: F2

ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 461,811
Date: 02 Feb 2026
Ownership: See footnote
Footnotes: F3

ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 113,287
Date: 02 Feb 2026
Ownership: See footnote
Footnotes: F4

ALXO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 54,083
Date: 02 Feb 2026
Ownership: See footnote
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The shares are held of record by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. The reporting person, a director of venBio Global Strategic GP II, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Footnote F2

The shares are held of record by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. The reporting person, a director of venBio Global Strategic GP, Ltd., disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Footnote F3

The shares are held of record by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. The reporting person, a managing director of venBio SPV, LLC, disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.

Footnote F4

The shares are held of record by the Goodman Barinaga Trust for which the reporting person serves as trustee.

Footnote F5

The shares are held of record by Emaldi Corporation for which the reporting person serves as a director. The reporting person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.